The α Chemokine, Interleukin 8, Inhibits the Antiviral Action of Interferon α

By Khalid S.A. Khabar,* Fahad Al-Zoghaibi,* Mohammed N. Al-Ahdal,* Tsugiya Murayama,† Mohammed Dhalla,* N aofumi M ukaida,‡ Mohammed Taha,* Sultan T. Al-Sedairy,* Yunus Siddiqui,* George Kessie,* and Kouji Matsushima

From the *Department of Biological and Medical Research, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia 11211; †Department of Microbiology, Kanazawa University, Ishikawa 920-0; ‡Department of Pharmacology, Kanazawa University, Kanazawa 920; and ††Department of Molecular Preventive Medicine, University of Tokyo, Tokyo 113, Japan

Summary

Interferon (IFN) exhibits a potent antiviral activity in vitro and plays a major role in the early defense against viruses. Like IFN, the proinflammatory chemokine, interleukin (IL)-8, is induced by viruses and appears in circulation during viral infections. In an in vitro cytopathic effect assay for IFN, we found that IL-8 can inhibit IFN-α activity in a dose-dependent manner. This action was reversed by specific monoclonal antibodies to IL-8. The chemokine was able to attenuate the IFN-mediated inhibition of viral replication as determined by measuring infectious virus yield. IL-8 also diminished the ability of IFN to inhibit an early stage of viral replication since IL-8 attenuated the inhibition of the formation of viral proteins. It appeared that IL-8 interfered with a late rather than an early step of IFN-mediated pathway such as early gene expression. The IL-8 inhibitory action on IFN-α antiviral activity was associated with reduced 2′,5′-A oligoadenylate synthetase activity, a pathway well correlated with the antencephalomyocarditis virus action of IFN-α. Understanding pathways that antagonize IFN action may lead to novel approaches to potentiate endogenous and therapeutic IFN.

Materials and Methods

Cells and Viruses. The human epithelial amnion WISH cell line (HeLa markers) was obtained from Dr. J.A. Armstrong (University of Pittsburgh, Pittsburgh, PA). Normal human fibroblasts were prepared from foreskin. VERO (African green monkey kid-
oney), L929 (mouse fibrosarcoma), THP-1 (human monocytic), and MRC-5 (human fibroblastic lung) cell lines were obtained from the American Type Culture Collection (Rockville, MD). All cell lines were grown at 37°C and 5% CO₂ in MEM (GIBCO BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (GIBCO BRL), except for THP-1 cells which were grown in RPMI 1640 with 10% fetal bovine serum (FBS).

EMCV, also obtained from Dr. J.A. Armstrong (University of Pittsburgh, Pittsburgh, PA), was propagated in L929 cells. Poliovirus type 1, vesicular stomatitis virus (VSV; Indiana strain), and HSV-1 strain F were obtained from the American Type Culture Collection and propagated in the VERO cell line. Virus preparations were clarified by low speed centrifugation, filtered through 0.22 μm paper, and concentrated by ultracentrifugation. All viruses were titrated in VERO with resultant titers of 2 × 10^7, 2 × 10^8, 8 × 10^8, and 1 × 10^9 PFU/ml for EMCV, poliovirus, VSV, and HSV-1, respectively. Plaque assays are described later. Viruses were aliquoted and stored at −70°C until use.

IFNs and IL-8. Human rIL-8 was expressed in Escherichia coli as previously described (14). Biological activity was assessed using neutrophil chemotaxis multwell Boyden chamber assay as described (15); maximum activity was observed at 10 ng/ml (15). Also, rIL-8 (Lot No. BA-044041; R&D Systems, Minneapools, MN) was occasionally used and similar results were obtained. When both rIL-8 were calibrated against the reference preparation 89/520 (National Institute for Biologicals Standardization and Calibration, Hertfordshire, UK), the maximum activity was in the vicinity of 100 IU/ml. Human rIFN-α2a, obtained from Hoffmann-La Roche (Basel, Switzerland), had a specific activity of 2 × 10^3 IU/mg, as reported by the manufacturer. A starting solution was made and calibrated with NIH Gxa01-901-535 IFN-α reference preparation; the titer was 10^7 IU/ml. rIFN-γ was obtained from Genzyme (Cambridge, MA) and had a specific activity of 10^7 IU/mg, according to the manufacturer. A starting solution was made and calibrated with NIH Gxg01-901-535 reference preparation; the titer was 10^6 IU/ml.

IFN Bioassay. The tetrazolium salt (MTS) IFN microtiter assay was used to assess potency of IFN-α by measuring end point titers. The assay has been previously described in detail (16). In some experiments, the crystal violet stain assay was used (17). When using either method, the OD was correlated with the degree of protection from virus-induced cytopathic effect (18). Percent cell protection was calculated as follows: 1 − ((dilution OD − virus control OD) / (cell control OD − virus control OD)) × 100%, where OD is optical density and dilution OD refers to an average OD in triplicate wells at the dilution specified. Percent cell protections were plotted against serial dilutions of the IFN preparation. End-point titers expressed as laboratory units per milliliter (LU/ml) were taken as reciprocals of dilutions that gave 50% cell protection. IFN doses (LU/ml, reciprocal of dilutions) were corrected to IU/ml by calibrating with the international reference standard described above.

Antibodies. A mouse anti-human IL-8 mAb of an IgG₁ isotype, W-5, was generated as previously described (18). The isotype-matched normal IgG was obtained from R&D Systems. Antibodies were incubated with IL-8 for 4 h at room temperature. Different molarity ratios were first assessed to determine optimum ratio; a ratio of 3:1 (antibody/IL-8) showed maximal reversal. For immunoprecipitation experiments, antisera to poliovirus was raised in guinea pigs; the virus was previously purified on sucrose gradient by ultracentrifugation and washed with Triton-HCl buffer (pH 7.4). The antisera was adsorbed to VERO cells to eliminate antibodies cross-reactive to cellular proteins.

Infectious Virus Yield Titration. For experiments that required virus yield titration, virus was added to cells for 1 h before supernatants were aspirated to remove unadsorbed virus particles. Culture plates were incubated for 24 h at 37°C. The cultures were subjected to freezing and thawing to lyse the cells. Cell lysates that contained both intracellular and extracellular particles were clarified from cell debris by centrifugation. PFU's in the resultant supernatants were quantitated according to standard methods (19) involving VERO cells. The overlay MEM contained either agar (Sigma Chemical Co., St. Louis, MO) in case of EMCV or methylcellulose (Sigma Chemical Co.) for other viruses. The plates were stained with crystal violet to quantitate PFU's.

Poliovirus Polypeptides: Membrane Labeling. Radioimmunoprecipitation, and SDS-PAGE. After cytokine and IFN treatments, VERO monolayers in 24-well plates were incubated with poliovirus for 1 h. The unadsorbed virus was removed by washing with PBS buffer. The cultures were incubated for 24 h with methionine-free MEM (GIBCO BRL) supplemented with 2% dialyzed FBS and 10 μCi of [35S]methionine (Amersham, Buckingham, U.K.). The radioactive medium was removed, and monolayers were washed in PBS. Cells were lysed in gel lysis radioimmunoprecipitation (RIPA) buffer (10 mM Tris-HCl, 15 mM NaCl, 1.5 M GcJ, 1% Triton X-100, 0.25% deoxycholate, 1 mM PMSF, and 15 μl of aproitin) on ice. Lysates were mixed with anti-poliovirus 1 anti-serum for overnight at 4°C. The immune complexes were precipitated using 10% suspension of protein A–Sepharose beads (Pharmacia, Uppsala, Sweden) in blocking buffer (1% BSA–PBS) for 1 h at 4°C. The beads were collected by centrifugation, washed five times, and resuspended in SDS sample buffer. The immune complexes were released into the supernatants by boiling and then electrophoresed in 12% SDS-PAGE. The gels were fixed, washed, dried, and visualized by autoradiography (Kodak XAR film; Kodak, Rochester, NY) at −70°C. Before immunoprecipitation, lysates were examined by 12% SDS-PAGE to verify quality and loading of total proteins. 14C-methylated protein molecular weight markers (14–220 kD) were used to verify the size of viral proteins.

RNA Preparation and Northern Blot Analysis. Total RNA was extracted by guanidine isothiocyanate method (20) using Trizol Reagent (Molecular Research Center, Cincinnati, OH). 20 μg of total RNA was electrophoresed through a 2.2% formaldehyde gel. Northern transfer was performed overnight using Zeta Probe nylon membrane (Bio-Rad, Hercules, CA). Membranes were baked and prehybridized in Express Hyb solution (Clonetech, Palo Alto, CA) in a Hybaid Mini Hybridization Oven (Labnet, Woodbridge, NJ). cDNA probes specific for the 0.7-kb RNA (American Type Culture Collection) were labeled with [32P]dCTP (Amersham) using nick translation kit (GIBCO BRL). The labeled probes were purified on Sephadex G-50 columns, denatured, added to Express Hyb solution, and hybridized for 1 h at 68°C. The blots were washed and exposed to Kodak X-Omat AR film (Sigma Chemical Co.), and the autoradiograms were subsequently developed.

Reverse Transcriptase PCR and Southern Blotting. In brief, the reverse transcriptase (RT) reaction was performed using 5 μg total RNA, 500 ng random hexamer (Random Primers; Promega, Madison, WI), 500 μM dNTP mixture, 20 U RNASin (Pharmacia), and 200 U of Moloney murine leukemia virus reverse transcriptase (GIBCO BRL). The samples were heated to inactivate RT. A pair of primers that amplify both IL-8R A and B (CXCRI and CXCRII; Maxim Biotech, Inc., San Francisco,
express hyb solution and hybridized for 1 h at 37°C. Sephadex G–50 column, denatured, and added to the membranes in a binding buffer (PBS, 1% BSA, and sodium azide) with 10 ng/μl England BioLabs, Beverly, MA). Labeled probes were purified on a Zeta probe nylon membrane (Bio Rad) Southern blotting using Zetaprobe nylon membrane (Bio Rad) in which the latter was measured by competitive radioimmunoassay. (Bio Rad) 5TGCTATGAGGACATG9GCCAACAATACAGCA39. The probes were labeled at 5′ end with [γ-32P]ATP (Amersham) using T4 polynucleotide kinase (New England BioLabs, Beverly, MA). Labeled probes were purified on a Sephadex G–50 column, denatured, and added to the membranes in ExpressHyb solution and hybridized for 1 h at 37°C. The blots were washed and exposed to Kodak X-Omat AR film (Sigma Chemical Co.), and the autoradiograms were subsequently developed.

The pair of primers that amplify 282-bp fragment for 2′,5′-oligoadenylate synthetase (OAS) and 838-bp fragment for β actin, and the oligonucleotide probe used to confirm OAS PCR fragments were previously described in detail (5). RT-PCR for OAS and β actin gene expression was performed essentially the same as above. The PCR conditions for OAS amplification allowed at least qualitative comparisons; e.g., significant stimulation or inhibition, of signal strength on agarose gels. These comparisons were validated by generating PCR products using different cycles in which the signal strength was within linearity up to 44 cycles. 

Competition Receptor Binding Assay. The binding assay was performed in 96-well U-bottom flexible plates (Falcon, Becton Dickinson; Bedford, MA). The wells were first coated overnight with FBS to reduce nonspecific binding (22). WISH or the CXCR-positive THP-1 cells (23) were seeded at 0.5 × 104/well and incubated in a binding buffer (PBS, 1% BSA, and sodium azide) with 106 cpm of 125I–IL-8 specific activity 2,000 Ci/mmol; Amersham) in the presence or absence of 750-fold molar excess of cold IL-8 in each microwell. Plates were then incubated at 4°C for 90 min, centrifuged in an Eppendorf centrifuge, and washed three times with PBS/BSA buffer. Cell-bound radioactivity was harvested from the wells in polystyrene tubes and quantified in gamma counter.

OAS Assay. The assay was described in detail elsewhere (5). In brief, cells were lysed by 0.5% N P-40-containing buffer. Equal amounts (1:50 dilution) of lysates were added to tubes containing polyI polyC–agarose at bottom to bind OAS, and unbound materials were washed off by centrifugation. ATP was added to assay tubes and incubated for 1 h at 37°C. OAS converts ATP to 2′-5′A in which the latter was measured by competitive radioimmunoassay. The amounts of 2′-5′A (pmol/dl) generated reflects OAS activity. All materials in OAS assay were obtained from Eiken Chemical Co. (Tokyo, Japan).

Statistical Analysis. All comparisons were performed with the Student’s paired t test with the aid of GraphPad Prism software (San Diego, CA). Significance was reported with two-tailed P < 0.005 unless otherwise described.

Results
Inhibitory Effect of IL-8 on IFN-α Antiviral Activity. We found that inclusion of recombinant IL-8 in an in vitro assay for IFN activity (16, 17) significantly reduced the potency of IFN-α. The assay measures the ability of IFN to protect human WISH epithelial cells from the cytopathic, (e.g., cytopathic) effects (CPE) induced by encephalomyocarditis virus. When target cells were pretreated with IL-8, 90% reduction in IFN-α potency (P < 0.005, paired Student’s t test) was consistently observed as assessed by measuring end-point titers (Fig. 1A). When the dosage was expressed in terms of international unitage, the ED50 of IFN-α activity increased from 1 to 10 IU/ml as a result of IL-8 treatment (Fig. 1B). IL-8 did not enhance EM CV-induced CPE at the virus challenge dose, multiplicity of infection equal to 0.1, used in the assay which gave near maximum (90–100%) CPE. Virus-induced CPE was 90 ± 4% and 95 ± 2% in the absence or presence of IL-8 (33 ng/ml), respectively. Also, IL-8 did not affect cell viability (MTS tetrazolium assay) which was 98 ± 4.5% of cell control in the presence of IL-8.

Dependence of IL-8 Inhibitory Potency on IFN Dose, IFN Type, and IL-8 Dose. The IL-8 inhibitory potency towards anti-EM CV IFN-α activity was more pronounced at lower IFN doses (Fig. 1). For example, at 20 IU/ml, the IFN-mediated inhibition of CPE was 90 and 70% in the absence and presence of IL-8 treatment, respectively. In contrast, at 1 IU/ml, the IFN-mediated inhibition of viral CPE decreased from 50 to 8% due to IL-8 treatment (Fig. 1B).

The inhibitory effect of IL-8 on IFN-α antiviral activity was dose dependent, yielding an ED50 of ~150 pg/ml (Fig. 2). Maximum inhibition was observed at 10 ng/ml (Fig. 2). No IL-8 toxicity was seen at the doses tested as judged by MTS tetrazolium dye; for example, at 100 ng/ml, cell control OD was 1.35 ± 0.02 (n = 4), whereas in the presence of 100 ng/ml of IL-8, the OD was 1.34 ± 0.04 (n = 4). Likewise, there was no toxicity observed using either try-
IL-8 inhibits the antiviral action of IFN-α. Dose-response relationships for IL-8 inhibition of IFN-α antiviral activity. Confluent WISH cells were pretreated with indicated concentrations of IL-8; cells were then used for the IFN bioassay as described in Materials and Methods. Percent inhibition refers to percent reduction in original IFN-α potency (10^7 IU/ml) in the absence of IL-8 treatment (IFN control, 0% inhibition). Average number of experiments (those with SEM) is four. *Statistical significance at P < 0.005 when compared to no IL-8 treatment. Other points could not be statistically analyzed because n = 2 is small.

IL-8 inhibitory effect on anti-EMCV IFN-α activity as assessed by reduction in IFN titers (Fig. 3A). Also, anti-IL-8 was able to reverse the IL-8 inhibitory action on IFN-α activity as assessed by the percentage of IFN-mediated cell protection from virally-induced CPE (Fig. 3B).

Expression of CXC CR (IL-8R) in WISH Cells. The IL-8 receptors, CXCR1 and CXCR2, are not only expressed on cells of hematopoietic origin such as neutrophils and monocytes, but also on cells of nonhematopoietic type (23–26). Using THP-1 cell line as a positive control for IL-8 receptor (23), we found that WISH cells also contained CXCR transcripts as assessed by RT-PCR (Fig. 4, top). To confirm the PCR products, a probe for highly conserved region of CXCR1 and CXCR2 was used in Southern analysis as revealed in Fig. 4 (bottom). The CXCR transcript was expressed at lower levels in WISH than in THP-1. This may be attributed to the presence of other homologous chemokine receptor sequences. The lower expression of CXCR in WISH than in THP-1 cells was also observed in radiobinding competitive experiments (Table 1). Specific binding of 125I–IL-8 due to 750-fold molar excess of unlabeled IL-8 was threefold lower in WISH than in THP-1. Also, unlabeled IL-8 competed less efficiently in THP-1 than in WISH cells (Table 1).

Effect of IL-8 on Infectious Virus Yield in IFN-treated Cells. Not only did IL-8 attenuate IFN-α antiviral action against virus-induced CPE, but also against the total (intracellular and extracellular) virus yield from infected cells (see Fig. 5). This may indicate that IL-8 antagonized IFN-α inhibitory action on viral replication. There was antagonism by IL-8 (four- to sixfold enhancement of virus yield) in EMCV-infected WISH cells treated with IFN-α doses at 10 IU/ml and lower (Fig. 5A). The inhibitory effect of IL-8 on IFN-

Figure 2. Dose-response relationships for IL-8 inhibition of IFN-α antiviral activity.

Figure 3. Specificity of IL-8 inhibition of IFN-α antiviral activity. (A) mAb to IL-8 (WS-4) and control isotype-matched IgG, both at a molar ratio of 3:1, were incubated before addition of IFN-α and followed by EMCV. Percent of IFN-α control (100%) refers to the original antiviral IFN-α potency in terms of IFN titers. Data are mean ± SEM of three experiments. (B) Experiments 1 and 2 denote percent inhibition of EMCV-induced CPE due to IFN-α (10 IU/ml). Cell protection was calculated as described in Materials and Methods. Results in each experiment represent the means ± SEM of triplicate cultures. *Statistical significance at P < 0.005 when compared to IFN control.

Figure 4. Expression of CXC CR (IL-8R) in THP-1 and WISH cell lines. Total RNA was extracted from WISH cells (lane 3) and THP-1 monocytic cells (positive control; reference 23, lane 4) and subjected to RT-PCR. PCR products generated from the primers that recognize both CXCR1 and CXCR2 corresponded to the expected size of 680 bp (middle arrow). Lane 1 denotes size markers and lane 2 represents PCR reaction including primers but no template. The lower panel shows specific signal (arrow) due to Southern hybridization with oligonucleotide directed to internal region of the PCR products (CXCR1 and CXCR2).
α-mediated suppression of virus yield was also seen with poliovirus, as EMCV it is positive-stranded RNA virus of the family picornaviruses. In this case, there was three- to sixfold increase in virus yield as a result of IL-8 treatment in IFN-treated poliovirus-infected WISH cells (Fig. 5 B). Although there was no direct IL-8 enhancement of CPE, which was maximum at the virus doses used, there was a slight enhancement (twofold) in virus yield in IL-8-treated cells used with the picornaviruses (Fig. 5, A and B). The inhibitory effect of IL-8 on IFN-α action was demonstrated with HSV-1 in MRC-5 (Fig. 5 C). With such DNA virus, higher doses (e.g., >30 IU/ml; Fig. 5 C) were required to suppress HSV-1 replication. Thus, in case of HSV-1, these high IFN-α concentrations were still subject to IL-8 effect. The inhibitory effect of IL-8 on IFN action could not be demonstrated with the negative-stranded VSV using either the virus-induced CPE (data not shown) or virus yield (Fig. 5 D) assays.

Effect of IL-8 on Poliovirus Protein Synthesis. IFNs are known to intervene with an early stage of picornaviral replication resulting in inhibition of the formation of viral proteins (1, 2). We had neutralizing antiserum of high titer to poliovirus type 1; poliovirus as EMCV is IFN-sensitive picornavirus and has limited number of distinct proteins. Fig. 6 illustrates that the antiserum recognized at least three of the four major capsid proteins of poliovirus: VP1 (34 kD), VP2 (28 kD), and VP3 (24 kD), in addition to another band that may represent one of the precursor or intracellular proteins.

**Table 1.** Competition of Binding by Radiolabeled and Unlabeled IL-8 to WISH and THP-1 Cell Lines

| Total binding | Specific binding (%) |
|----------------|---------------------|
| Cells | 125I–IL-8 | 125I–IL-8 + excess unlabeled IL-8 | Specific binding (%) |
| WISH | 4,350 ± 1,076 | 2,898 ± 462 | 1,451 ± 649 (33) |
| THP-1 | 8,863 ± 1,730 | 3,923 ± 816 | 4,431 ± 918 (50) |

*5 × 10⁵ cells were used with 10⁶ cpm of 125I–IL-8 in a radiobinding competition assay in the absence or presence of 750-fold molar excess of unlabeled IL-8. *Percent of total binding. Results are the average of three independent experiments with SEM.

**Figure 5.** Effect of IL-8 on virus yield in IFN-treated cells. Confluent cells in microtiter plates were pretreated overnight with IL-8 (10 ng/ml) followed by IFN-α at indicated concentrations for 20 h. Viruses were added at doses that were previously determined to cause maximum CPE within 24 h. The following virus cell systems were used: EMCV/WISH (A), poliovirus/WISH (B), HSV-1/MRC-5 (C), and VSV/normal fibroblasts (D). Infectious virus yield was quantitated in terms of PFU/ml as described in Materials and Methods. IL-8 itself had no effect on the CPE. Data are from an average of three experiments. *Statistical significance at P < 0.005 when compared to IFN alone at the indicated concentrations. VC, virus control; VC + IL-8, virus control that was treated with IL-8. All other treatments, as indicated, are in the presence of virus.
The inhibition of the formation of 35S-labeled poliovirus proteins showed a clear dose response by IFN-α (Fig. 6). IL-8 was able to attenuate the IFN-mediated inhibition of the formation of poliovirus proteins (Fig. 6). IL-8 reversed the IFN-mediated inhibition of viral proteins synthesis particularly at doses 0.1 and 1 IU/ml of IFN-α. IL-8 itself did not significantly upregulate the protein bands (Fig. 6) with the cytopathic challenge used in the experiments.

Kinetics of IL-8 Inhibitory Action on IFN-α Antiviral Activity and Lack of IL-8 Interference with Early IFN Response. The IL-8 inhibitory effect on IFN activity was similarly demonstrated whether IL-8 was added before, simultaneously with, or as late as 20 h after IFN treatment (Fig. 7). This suggests that IL-8 exerted its inhibitory action at a late rather than early step in IFN-mediated pathway. As shown in Fig. 8, this was also supported by the lack of changes in mRNA expression of the 6-16 gene (27) that contains the IFN-α-stimulated response element that is conserved in most IFN-α responsive genes (28).

Effect of IL-8 on the IFN-regulated OAS Activity. We looked at the constitutive OAS pathway, a pathway that was reported to correlate with IFN-α action against EMCV, but not VSV (1, 2). Both EMCV, substantially, and VSV, moderately, were associated with lower OAS activity, probably due to their general cytopathic perturbation of the cells (Fig. 9). However, IL-8 action was associated with further reduction in OAS activity in the EMCV-infected IFN-treated cells (Fig. 9). The IL-8 suppressive action on OAS activity in the presence of IFN-α appears to be linked to the type of the virus since this was not seen with anti-VSV IFN-α activity (Fig. 9). IL-8 (10 ng/ml) had minimum effect on the cellular constitutive OAS activity in the presence or absence of IFN-α (Fig. 9). However, at high doses, e.g., 100 ng/ml, there was 38% inhibition of OAS activity in WISH cells without affecting cell viability; in three independent experiments, the OAS activity was 25,800 ± 6,025 and 17,442 ± 3,990 in the absence or presence of 100 ng/ml, respectively. It appeared that IL-8 had no dramatic effect, e.g., significant inhibition, on IFN-α-induced mRNA expression of OAS as assessed by RT-PCR (Fig. 10), supporting the hypothesis that IL-8 apparently blocked the antiviral action of IFN-α at late, e.g., OAS activity, rather than early stage.

Discussion

Recently, chemokines have attracted the attention of the biomedical community because of their protective role in HIV infections and the reports of an ever increasing number of chemokines with novel functions (29–32). In this study, we have also demonstrated a novel role for one member of the chemokine family that, to the best of our knowledge, has not been previously described. In short, we have provided evidence for the IL-8 inhibition of the antiviral action of IFN-α in several virus-cell systems with emphasis on EMCV and HeLa line (WISH) as a well-studied model for IFN action.

The potency of the IL-8 inhibitory effect on IFN-α antiviral action observed here was dependent on IFN-α and IL-8 doses. The action of IL-8 was more potent at lower IFN doses (<30 IU/ml). These are still within the physiological concentrations in plasma of healthy individuals, patients with viral diseases, and even patients undergoing some IFN therapy regimens (33–35). The IL-8 doses shown in this report to be effective in inhibition of IFN-α antiviral action were also observed in plasma of subjects with various inflammatory and viral infections (36–38).
We also demonstrated here that the inhibitory action of IL-8 on IFN-α antiviral activity was observed at different stages of virus life cycle: viral protein formation, total virus yield, and CPE. It is likely that IL-8 action interferes with IFN-mediated inhibition of viral replication since both the biosynthesis of viral protein and total virus yield were compromised by IL-8. Of these three, the earliest stage is the formation of viral proteins. There are two well-characterized pathways for IFN action that results in inhibition of viral proteins, namely, OAS/RNAse L and double-stranded dependent protein kinase (PKR) pathways. OAS/RNAse L is thought to control picornaviral viruses such as EMCV and Mengo virus, but not VSV replication (39–41). Our observations have demonstrated that IL-8 inhibits IFN-α antiviral action against the picornaviruses, EMCV, and poliovirus, but not against VSV. Also, reduction in OAS activity was seen with EMCV, but not VSV in IFN-treated cells. Taking these observations together with our previous observations that showed that IL-8 action in EMCV-infected, unlike VSV-infected, cells were associated with decreased OAS activity (5), suggest that OAS is the late stage that may be subject to IL-8 action. Thus, the IL-8 selective action in certain virus–cell systems may be related to which of the multiple mechanisms that is regulated by IFN to control the replication of the virus (1, 2, 42). For example, IFN inhibition of HSV-1 replication may not be attributed to OAS pathway, and the mechanism of IL-8 inhibitory action on IFN-α activity against HSV-1 may well be different from those against the picornaviruses.

The observations regarding the timing of IL-8 addition with respect to IFN-α treatment may indicate that IL-8 induced a nearly IFN-resistant state in the cells before virus challenge. Also, IL-8 appeared to work at a stage later than IFN-induced gene expression and protein synthesis, both of which are normally completed within several hours after IFN treatment (43). This hypothesis is supported by the observation that no suppressive influence of IL-8 on IFN-induced expression of 6-16 and OAS genes was qualitatively seen. Thus, it is more likely that the mechanism of IL-8 action in inhibiting IFN-α antiviral action occurs on OAS pathway in a manner that is probably independent of gene expression.

The capacity of viruses to induce IL-8 in vitro and in vivo (3, 6–8, 36–38), the enhancement of viral replication by IL-8 (4, 5), and the interference with IFN-α antiviral action against viruses may constitute a common strategy by which viruses take advantage of the host proteins for their own survival. This is opposite to the IFN system, which is to protect cells from viruses, and also shown to inhibit IL-8 synthesis (44).

In the present investigation, we used picornaviruses, such as EMCV, that are common in the study of IFN system (1, 40–42). Aside from EMCV and poliovirus, IFN-α-mediated inhibition of HSV-1 replication seems to be also compromised by IL-8. However, it is not known whether IL-8 inhibits IFN action against other viruses such as HIV. Recently, it was reported that β chemokines (RANTES, macrophage inhibitory protein-1α, and -1β) and the α chemokine stromal-derived factor 1 can inhibit HIV binding to the coreceptor CC-CKR-5 and CXC-CKR-3, respectively (for review see reference 29). This is not necessarily in conflict with the notion of a potential antagonizing effect of IL-8 on IFN action in HIV infections. IL-8 binds to different receptors, CXCR1 and CXCR2, that are expressed by several types of leukocytes and cell types of non-hematopoietic origin including WISH epithelial cells (our results), fibroblasts, endothelial cells, and keratinocytes (23–26).

The presence of IL-8 induced by viruses or other stimuli may contribute, at least partly, to the low potency of IFN in vivo during therapy and disease. Careful assessment of these hypothesis in animal models is required. Interference with IL-8 production or action may suppress viral activity and/or augment endogenous IFN-α antiviral action against selected viruses. Also, intervention of IL-8 action or production may be useful as a mean of supplementing IFN-α therapy and hence, enhancing of IFN-α antiviral potency or reduction of its toxicity.

Figure 9. Effect of IL-8 on the IFN-regulated OAS activity. WISH monolayers in 24-well plates were treated with IL-8 (10 ng/ml), treated with IFN-α (10 IU/ml), and infected with EMCV or VSV; control treatments received no virus. Each treatment (in duplicate wells for each experiment) continued for 16–18 h. IL-8 had no effect on cell viability. WISH cells produce high constitutive levels of OAS and IFN-α at 10 IU/ml induced further moderate OAS activity. OAS biochemical activity was assessed by measuring 2',5'-oligoadenylate generated from ATP by OAS action (see Materials and Methods). Average number of experiments are three. *Statistical significance at P < 0.01 when compared to values of any column in the group designated No Virus. C, denote cells.

Figure 10. Effect of IL-8 on IFN-regulated OAS mRNA gene expression. WISH cells were pretreated with medium or IL-8, 4 or 18 h overnight (0/N), followed by medium or 30 IU/ml IFN-α for 4 h. RNA was reverse transcribed, amplified with primers for OAS and β actin, and gel electrophoresed. Lane designations are as indicated on figure. RT-PCR conditions for OAS gene expression allowed, at least, qualitative comparisons, e.g., significant stimulation or inhibition of signal strength. Identity of OAS fragment was confirmed with oligoprobe specific to OAS (not shown). Experiment is one of three performed.
We would like to thank Dr. John A. Armstrong (University of Pittsburgh, Pittsburgh, PA), and Dr. Malcolm Paterson (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) for critical review of the manuscript. We also thank Dr. Sandra Pellegrini (Pasteur Institute, Paris, France) not only for supplying the 6-16 cDNA probe, but also for her helpful comments. The technical assistance of Maud Dzimiri is acknowledged. The authors thank Royal Purchasing Services of King Faisal Hospital and Research Center in Maryland (H anover M D) for expedient shipping of biological and other materials.

Address correspondence to Dr. Khalid S.A. Khabar, Head, Interferon and Cytokine Research Unit, Department of Biological and Medical Research, MBC-03, King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Saudi Arabia. Phone: 966-1-442-7878; FAX: 966-1-442-7858; E-mail: khabar@kfshrc.edu.sa

Received for publication 5 June 1997 and in revised form 25 July 1997.

References

1. Pestka, S., J. A. Langer, K. C. Zoon, and C. E. Samuel. 1987. Interferons and their actions. Annu. Rev. Immunol. 56:727–777.

2. Sen, G. C., and P. Lengyel. 1982. The interferon system. A bird’s view of its biochemistry. J. Biol. Chem. 267:5017–5020.

3. Murayama, T., Y. O hara, M. O buchi, K. S. A. Khabar, H. Higashi, N. M uka d a, and K. M atushima. 1997. Human cy to megalovirus induces IL-8 production by a human monocyte cell line, THP-1, through acting concurrently on AP-1 and NF-kB binding sites of the interleukin-8 gene. J. Virol. 71:5692–5695.

4. Murayama, T., K. Kuno, F. Jisaki, D. Sakamuro, T. Furukawa, N. M uka d a, and K. M atushima. 1994. Enhancement of human cytomegalovirus replication in a human lung fibroblast cell line by interleukin-8. J. Virol. 68:7582–7585.

5. Khabar, K. S. A., F. Al-Zoghaibi, T. M urayama, K. M atushima, N. M uka d a, Y. Siddiqui, M. Dhal a, and M. N. Al-Ahdal. 1997. Interleukin-8 selectively enhances cytopathic effect (CPE) induced by positive-strand RNA viruses in the human WISH cell line. Biochem. Biophys. Res. Commun. 235:774–778.

6. Choi, A. M., and D. B. Jacoby. 1992. Influenza virus A infection induces interleukin-8 gene expression in human airway epithelial cells FEBS Lett. 309:327–329.

7. Fiedler, M. A., K. Werek e-Doll ries, and J. M. Stark. 1996. Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am. J. Physiol. 269:865–872.

8. Sheth, R., J. Anderson, T. Sato, B. O h, S. H. Hemp son, E. R ollo, E. R. M a ck ow, and R. D. Shaw. 1996. R otavirus stimulation induces IL-8 secretion from cultured epithelial cells. Virology. 221:251–259.

9. Baruch-Ben, A., D. F. Michiel, and J. J. Oppenheim. 1995. Signals and receptors involved in recruitment of inflammatory cells. J. Biol. Chem. 270:11703–11706.

10. Oppenheim, J. J., C. C. O. Zachariae, N. M uka d a, and K. M atushima. 1991. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu. Rev. Immunol. 9:617–618.

11. Taub, D. D., M. Anver, J. J. Oppenheim, D. L. Longo, and W. J. M urphy. 1996. T lymphocyte recruitment by interleukin-8. IL-8 induced degradation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J. Clin. Invest. 97:1931–1941.

12. Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Eliner, S. G. Elner, and R. M. Strieter. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (Wash. D. C.). 258:1798–1801.

13. Cacalano, G. J., J. Lee, K. Kikly, A. M. R yan, S. Pitts-M eek, B. H ultgren, W. J. W ood, and M. W. M oore. 1994. N eutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science (Wash. D. C.). 265:682–684.

14. Matsushima, K., K. M orishita, T. Y oshim a, S. Lav u, Y. K obayashi, W. Lew, E. A pella, H. F. Kung, E. J. Leonard, and J. J. Oppenheim. 1988. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin-1 and tumor necrosis factor. J. Exp. Med. 167:1883–1893.

15. Furuta, R., J. Yamagashi, H. Kotani, F. Sakamoto, T. Fukui, Y. M atsui, Y. S ohmura, M. Y amada, T. Y os hima, C. G. Larsen, J. J. Oppenheim, and K. M atushima. 1989. Production and characterization of recombinant human neutrophil chemotactic factor. J. Biochem. (Tokyo). 106:436–441.

16. Khabar, K. S. A., F. Al-Zoghaibi, M. Dzimiri, M. Taha, A. Al-Tuwairi, and M. N. Al-Ahdal. 1996. MTS interferon assay: a simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt. J. Interferon Cytokine Res. 16:31–33.

17. Armstrong, J. A. 1980. Cytotoxic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol. 78:381–387.

18. Ko, Y. N., N. M uka d a, A. Pamyutich, N. N. Voiten k, K. M atushima, T. K awai, and T. K azahara. 1992. Establishment of a sensitive enzyme-linked immunosorbent assay for human interleukin-8. J. Immunol. M ethods. 149:227–235.

19. Lewis, J. A. 1991. Antiviral activity of cytokines. In Cytokines A Practical Approach. F. R. B alkwi ll, editor. Oxford University Press, Oxford. 109–120.

20. Choczynski, P., and N. Sacci. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.

21. Murphy, P. M., and H. L. Tiff any. 1991. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science (W ash. D. C.). 253:1280–1283.

22. Higuchi, M., and B. B. Aggarwal. 1992. Microtiter plate radioreceptor assay for tumor necrosis factor and its receptor in large numbers of samples. Anal. Biochem. 204:53–58.

23. Grob, P. M., E. David, T. C. W arren, R. P. D eLeon, P. R. F arina, and C. A. H omon. 1990. Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/ interleukin-8. J. Biol. Chem. 265:8311–8316.

24. Kemeny, L., A. S. Kendersky, I. Oczyszcz, G. Michel, T. Ruzicka, and A. Dobroz. 1995. Interleukin-8 induces IL-10 expression on cultured human keratinocytes via specific receptors. Int. Arch. Allergy Immunol. 106:251–256.
25. Mueller, S.G., W.P. Schraw, and A. Richmond. 1994. Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells. J. Biol. Chem. 269:1973–1980.

26. Schönbeck, U., E. Brandt, F. Petersen, F. Dieter-Han, and H. Loppnow. 1995. IL-8 specifically binds to endothelial but not smooth muscle cells. J. Immunol. 154:2375–2383.

27. Pellegrini, S., J. John, M. Shearer, I.M. Kerr, and G.R. Stark. 1989. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol. Cell. Biol. 9:4605–4612.

28. Darnell, J.E., I.M. Kerr, and G.R. Stark. 1994. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash. DC). 264:1415–1421.

29. Balter, M. 1996. A second coreceptor for HIV in early stages of infection. Science (Wash. DC). 272:1740.

30. Godiska, R., D. Chantry, C.J. Raport, S. Sozzani, P. Allavena, D. Leviten, A. Mantovani, and P.W. Gray. 1997. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185:1595–1604.

31. Mackay, C.R. 1996. Chemokine receptors and T cell chemotaxis. J. Exp. Med. 184:799–802.

32. Patel, V.P., B.L. Kreider, Y. Li, H. Li, K. Leung, T. Salcedo, B. Nardelli, Y. Pippalla, S. Gentz, R. Thotakura, et al. Molecular and functional characterization of two novel human C–C chemokines as inhibitors of two distinct classes of myeloid progenitors. J. Exp. Med. 185:1163–1172.

33. Bernier, J., A. Reuter, Y. Vrindts-Gevaert, and P. Franchimont. 1984. Radioimmunoassay of leukocyte (alpha) interferon and its application to some clinical conditions. J. Nucl. Med. 25:765–772.

34. Bornemann, L.D., H.E. Spiegel, Z.E. Dziewanowska, S.E. Krown, and W.A. Colburn. 1985. Intravenous and intramuscular pharmokinetics of recombinant leukocyte A interferon. Eur. J. Clin. Pharmacol. 28:469–471.

35. Shibazawa, S., N. Yoshikawa, K. Iijima, and K. Negishi. 1988. A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection. Clin. Exp. Immunol. 73:366–369.

36. Matsuzato, T., T. Miike, R.P. Nelson, W.L. Trudeau, R.F. Lockety, and J. Yodoi. 1993. Elevated serum levels of IL-8 patients with HIV infections. Clin. Exp. Immunol. 93:149–151.

37. Johnston, S.L. 1995. Natural and experimental rhinovirus infections of the lower respiratory tract. Am. J. Respir. Crit. Care Med. 152:546–52.

38. al-Wabel, A., B. al-Knawy, and S. Raziuddin. 1995. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis. Clin. Immunol. Immunopathol. 74:231–235.

39. Chebath, J., P. Benech, M. Ravel, and M. Vegneron. 1987. Constitutive expression of (2–5′) oligo A synthetase confers resistance to picornavirus infection. Nature (Lond.). 330:587–588.

40. Hassel, B.A., A. Zhou, C. Stomayor, A. Maran, and R.H. Silverman. 1993. A dominant negative mutant of 2-5A-dependent RNA suppresses antiproliferative and antiviral effects of interferon. EMBO (Eur. Mol. Biol. Organ.) J. 12:3297–3304.

41. Rysecki, G., D. Gewart, and B. Williams. 1990. Constitutive expression of (2–5′)-oligo A synthetase cDNA results in increased antiviral activity and growth suppression. J. Interferon Res. 9:649–657.

42. Samuel, C.E. 1991. Antiviral action of interferon: interferon-regulated cellular proteins and surprisingly selective antiviral activities. Virology. 183:1–11.

43. Tanaka, N., and T. Taniguchi. 1992. Cytokine gene expression: regulatory cis-elements and DNA binding factors involved in the interferon system. Adv. Immunol. 52:263–281.

44. Oliveira, I.C., N. Mukaida, K. Matsushima, and J. Vilcek. 1994. Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-κB site. Mol. Cell. Biol. 14:5300–5308.